News & Updates

Early antihypertensive treatment appears to have no significant benefits in terms of dependency or death at 90 days among patients with mild-to-moderate acute ischaemic stroke and systolic blood pressure (SBP) between 140 and <220 mm Hg, reports a study.

In the phase III ARCADIA 1 and 2 trials, the investigational, first-in-class interleukin-31-Rα antagonist nemolizumab delivered early, rapid, and sustained improvements in the core signs and symptoms of atopic dermatitis (AD) in patients with moderate-to-severe disease.

In patients with rheumatoid arthritis (RA), use of systemic glucocorticoids (GC) is associated with a time- and dose-dependent increase in risk of major adverse cardiovascular events (MACE), a population-based real-world study has shown. On long-term follow-up, a prednisolone dose of ≥5 mg/day is associated with a doubled risk of MACE vs no GC use, and no safe duration of use is found for this daily GC dose.

Dapagliflozin reduced HbA_1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

Personal poverty, as defined by not driving a personal vehicle to the appointment, and neighbourhood-level poverty appear to contribute to higher rates of screening positive for glaucoma or suspected glaucoma, suggests a study.